Despite widespread assumptions that psychopathy is associated with serious and repeated law-breaking, individuals with psychopathic personality traits do not invariably become chronic criminal offenders. As a partial explanation for this finding, Lykken (1995) ventured that a fearless temperament underlies both psychopathic traits and heroic behavior, and that heroic individuals’ early exposure to effective socializing forces such as warm parenting or healthy self-esteem often fosters a characteristic adaption that tends to beget “successful” behaviors, thereby differentiating heroes from convicts. In this study, we investigate relations between psychopathy, principally its fearless dominance dimension, pride, and prosocial and antisocial behavior in a community sample (N = 339). Fearless dominance and self-centered impulsivity components of psychopathy yielded differential relations with authentic and hubristic pride (Tracy and Robins, 2004), such that fearless dominance was significantly positively correlated with both facets of pride while self-centered Impulsivity was significantly negatively correlated with authentic pride and significantly positively correlated with hubristic pride. Further, authentic pride moderated (potentiated) the relation between fearless dominance and transformational leadership, one of the two outcome measures for prosocial behavior employed in our investigation. Authentic pride did not moderate the relations between fearless dominance and either our other measure of prosocial behavior (heroism) or antisocial behavior, nor did positive parenting moderate the relations between psychopathy components and social behavior. Unexpectedly, hubristic pride significantly moderated the relation between impulsive-antisocial features and antisocial behavior in a protective manner.

No abstract

Background High-grade gliomas (HGG) comprise the most common primary adult brain cancers and universally recur. Combination of re-irradiation therapy (reRT) and bevacizumab (BVZ) therapy for recurrent HGG is common, but its reported efficacy is mixed. Objective To assess clinical outcomes after reRT ± BVZ in recurrent HGG patients receiving stereotactic radiosurgery (SRS), hypofractionated radiosurgery (HFSRT), or fully fractionated radiotherapy (FFRT). Methods We performed a systematic review of PubMed, Web of Science, Scopus, Embase, and Cochrane databases, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We identified studies reporting outcomes for patients with recurrent HGG treated via reRT ± BVZ. Cohorts were stratified by BVZ treatment status and re-irradiation modality (SRS, HFSRT, and FFRT). Outcome variables were overall survival (OS), progression-free survival (PFS), and radiation necrosis (RN). Results Data on 1399 patients was analyzed, with 954 patients receiving reRT alone and 445 patients receiving reRT + BVZ. All patients initially underwent standard-of-care therapy for their primary HGG. In a multivariate analysis that adjusted for median patient age, WHO grade, RT dosing, reRT fractionation regimen, time between primary and re-irradiation, and re-irradiation target volume, BVZ therapy was associated with significantly improved OS (2.51, 95% CI [0.11, 4.92] months, P = .041) but no significant improvement in PFS (1.40, 95% CI [− 0.36, 3.18] months, P = .099). Patients receiving BVZ also had significantly lower rates of RN (2.2% vs 6.5%, P < .001). Conclusions Combination of reRT + BVZ may improve OS and reduce RN rates in recurrent HGG, but further controlled studies are needed to confirm these effects.

No abstract